TrialThe Lancet. Infectious diseases2022

Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.

James Welker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.